Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis by C. Rampinelli et al.
the bmj | BMJ 2017;356:j347 | doi: 10.1136/bmj.j347
RESEARCH
1
open access
1Department of Medical 
Imaging and Radiation 
Sciences, European Institute of 
Oncology, Milan, Italy
2Medical Physics School, 
University of Milan, Milan, Italy
3Division of Medical Physics, 
European Institute of Oncology, 
Milan, Italy
4Division of Epidemiology and 
Biostatistics, European Institute 
of Oncology, Milan, Italy
5Division of Thoracic Surgery, 
European Institute of Oncology, 
Milan, Italy
6Division of Thoracic Surgery, 
Humanitas Research Hospital, 
Rozzano, Italy
7Department of Oncology and 
Hematology-Oncology, 
University of Milan, Milan, Italy
Correspondence to:  
C Rampinelli  
cristiano.rampinelli@ieo.it
Cite this as: BMJ 2017;356:j347
http://dx.doi.org/10.1136/bmj.j347
Accepted: 29 December 2016
Exposure to low dose computed tomography for lung cancer 
screening and risk of cancer: secondary analysis of trial data 
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ABSTRACT
ObjeCtive
To estimate the cumulative radiation exposure and 
lifetime attributable risk of cancer incidence 
associated with lung cancer screening using annual 
low dose computed tomography (CT).
Design
Secondary analysis of data from a lung cancer 
screening trial and risk-benefit analysis.
setting
10 year, non-randomised, single centre, low dose CT, 
lung cancer screening trial (COSMOS study) which took 
place in Milan, Italy in 2004-15 (enrolment in 2004-05). 
Secondary analysis took place in 2015-16.
PartiCiPants
High risk asymptomatic smokers aged 50 and older, 
who were current or former smokers (≥20 pack years), 
and had no history of cancer in the previous five years.
Main OutCOMe Measures
Cumulative radiation exposure from low dose CT and 
positron emission tomography (PET) CT scans, 
calculated by dosimetry software; and lifetime 
attributable risk of cancer incidence, calculated from 
the Biological Effects of Ionizing Radiation VII (BEIR VII) 
report.
results
Over 10 years, 5203 participants (3439 men, 1764 
women) underwent 42 228 low dose CT and 635 PET CT 
scans. The median cumulative effective dose at the 
10th year of screening was 9.3 mSv for men and 13.0 
mSv for women. According to participants’ age and 
sex, the lifetime attributable risk of lung cancer and 
major cancers after 10 years of CT screening ranged 
from 5.5 to 1.4 per 10 000 people screened, and from 
8.1 to 2.6 per 10 000 people screened, respectively. In 
women aged 50-54, the lifetime attributable risk of 
lung cancer and major cancers was about fourfold and 
threefold higher than for men aged 65 and older, 
respectively. The numbers of lung cancer and major 
cancer cases induced by 10 years of screening in our 
cohort were 1.5 and 2.4, respectively, which 
corresponded to an additional risk of induced major 
cancers of 0.05% (2.4/5203). 259 lung cancers were 
diagnosed in 10 years of screening; one radiation 
induced major cancer would be expected for every 108 
(259/2.4) lung cancers detected through screening.
COnClusiOn
Radiation exposure and cancer risk from low dose CT 
screening for lung cancer, even if non-negligible, can 
be considered acceptable in light of the substantial 
mortality reduction associated with screening.
Introduction
Lung cancer is the leading cause of cancer for both men 
and women in the USA. In 2015, the American Cancer 
Society expected more than 200 000 new cases of lung 
cancer, about 14% of the total new cancers, with a five 
year survival rate of 18%.1
The US National Lung Screening Trial has shown that 
screening of high risk populations with low dose com-
puted tomography (CT) reduces lung cancer mortality 
by more than 20% when compared with chest radiogra-
phy.2  As a consequence, several medical societies cur-
rently recommend CT lung screening, and in the USA, 
the Centers for Medicare and Medicaid Services have 
granted a positive insurance coverage decision on 
screening.3 Millions of healthy high risk individuals are 
therefore theoretically eligible for CT lung cancer 
screening.
There is concern, however, that exposure to the ion-
ising radiation of low dose CT in lung cancer screening 
might increase the risk of developing solid cancers and 
leukaemia.4  The concrete existence of this increased 
risk as related to low dose radiation (doses <50 mSv) is 
controversial,5-7 although this topic deserves  additional 
consideration because ionising radiation from CT 
screening is delivered to healthy people.
So far, there is limited knowledge of the levels of radi-
ation exposure in lung cancer screening regarding both 
cumulative radiation exposure and the associated can-
cer risk, particularly in long term studies. Brenner8 
WhAT IS AlReAdy knoWn on ThIS TopIC
Lung cancer is the leading cause of cancer death among both men and women
Screening of high risk individuals with low dose computed tomography reduces 
lung cancer mortality by 20% if compared with chest radiography
Excess cancer risks related to ionising radiation from low dose computed 
tomography are a major concern in lung cancer screening
WhAT ThIS STudy AddS
The median cumulative radiation exposure from low dose computed tomography 
screening over 10 years was 9.3 mSv for men and 13.0 mSv for women
The lifetime attributable risk of major cancers from low dose computed tomography 
screening ranged from 2.6 to 8.1 major cancers per 10 000 participants, according 
to participant age and sex
One radiation induced cancer would be expected in every 108 lung cancers 
detected after 10 years of computed tomography screening
Radiation exposure from low dose computed tomography and the risk of radiation 
induced cancer can be considered acceptable in light of the substantial mortality 
reduction associated with lung cancer screening
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 estimated that if 50% of all current and former smokers 
in the US population aged 50-75 received annual CT 
screening, the number of lung cancers associated with 
radiation from screening would be about 36 000, a 1.8% 
(95% confidence interval 0.5 to 5.5) increase over the 
otherwise expected number. McCunney and Li9 reported 
that lung screening participants could experience a 
cumulative exposure to ionising radiation over 20-30 
years, which exceeds the lifetime dose experienced by 
nuclear power workers and atomic bomb survivors. The 
results of these studies cannot be considered conclusive, 
however, because they are based on the assumption of 
an arbitrary, pre-established radiation dose for all indi-
viduals, regardless of sex, age, or body size.
The aim of this study was to retrospectively evaluate 
the cumulative radiation exposure and lifetime attribut-
able risk of cancer incidence associated with low dose 
CT from a 10 year lung cancer screening programme.
Methods
All data reported in the present study were retrospec-
tively assembled and analysed from a 10 year, non-ran-
domised, observational, lung cancer screening trial 
(COSMOS study).10 11 In brief, 5203 asymptomatic high 
risk participants (age >50 and smoking history with ≥20 
pack years, and no history of cancer in the past five 
years) underwent annual low dose CT for 10 consecu-
tive years. Additional recalls for suspicious findings 
were performed with low dose CT scans and positron 
emission tomography (PET) CT scans, according to the 
study design. The COSMOS study took place in Milan, 
Italy, in 2004-15 (enrolment in 2004-05).A comprehen-
sive description of the COSMOS study, as well as low 
dose CT protocols and PET CT scans, are reported in the 
supplementary material. The present study (that is, the 
secondary analysis), took place in 2015-16.
radiation exposure from Ct screening
To consider the overall radiation exposure in the popu-
lation, the annual repeated low dose CT scans and the 
follow-up low dose CT scans of each patient were col-
lected for each year of screening. In addition, all the PET 
CT scans performed within the study were considered to 
evaluate the cumulative exposure dose. At the end of the 
10th year of CT screening, all performed examinations 
were collected from the radiology information-picture 
archiving and communication system (RIS-PACS) and 
sent to Radimetrics (Bayer Healthcare), a commercially 
available software for monitoring and tracking patient 
radiation exposure.12 Organ doses and effective doses 
were retrospectively estimated by Radimetrics for each 
low dose CT examination and for the CT acquisitions of 
the PET CT scans. Data and scanning parameters were 
collected from CT examinations, and patients were 
matched—according to age, sex, weight, and dimen-
sion—to six and five different adult phantoms for women 
and men, respectively. This size specific calculation of 
organ doses is more accurate than calculating from the 
standard reference patient used by other software.
Organ doses are calculated by use of a look-up table 
based on MonteCarlo simulations for the selected 
 phantoms,13  and are used to estimate effective dose 
according to weighting factors from the International 
Commission on Radiological Protection.14  For PET CT 
scans, the contribution of the radioactive tracer to 
organ doses and effective doses is calculated by the 
absorbed dose coefficients per unit activity adminis-
tered (mGy/MBq).15
Total estimated organ dose and effective dose for one 
patient were calculated as the sum of the doses of each 
low dose CT examination (screening rounds performed 
plus recalls) and PET CT scans when performed. 
Because cumulative organ and effective doses were 
non-normally distributed, median and range were con-
sidered.
Cancer risk estimation
For each age, sex, and organ, we determined the life-
time attributable risk of cancer incidence from a 100 
mSv organ equivalent dose table 12D-1 of the National 
Research Council’s Biological Effects of Ionizing Radia-
tion VII (BEIR VII) report.4 When missing, age specific 
lifetime attributable risk was estimated by polynomial 
interpolation of lifetime attributable risk values 
reported for ages 50, 60, 70, and 80. This lifetime attrib-
utable risk from a theoretical 100 mSv organ dose was 
scaled linearly on the basis of the actual organ dose 
measured at each CT scan. Lifetime attributable risk 
was calculated for each of the 42 228 low dose CT scans 
performed during the COSMOS trial and added together 
to calculate the lifetime attributable risk for the entire 
COSMOS population.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
radiation exposure from Ct screening
During the 10 years of the COSMOS lung cancer screen-
ing trial, 5203 high risk participants underwent 42 228 
low dose CT examinations, including 39 981 annual CT 
scans, 1965 first recall CT scans, and 282 second recall 
CT scans for lung cancer screening. As part of the 
screening protocol, 635 PET CT scans were performed in 
522 participants with suspicious findings (table 1). A 
total of 259 lung cancers were diagnosed after 10 years 
of CT screening.
The median effective dose delivered at the baseline 
screening round was 1.0 mSv (range 0.6-16.5) for men 
and 1.4 mSv (0.9-14.9) for women. Median cumulative 
effective doses from both low dose CT and PET CT scans 
at the third, fifth, and 10th year of screening were 3.0 
mSv (1.9-27.4), 5.2 mSv (2.9-39.6), and 9.3 mSv (5.6-42.7) 
for men, respectively; and 4.2 mSv (2.9-23.3), 7.2 mSv 
(4.1-26.8), and 13.0 mSv (8.0-33.5) for women, respec-
tively (table 2). A PET CT scan delivered an additional 
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median radiation exposure of 4.0 mSv (1.2-28.8). Com-
plete information on the effective doses and organ spe-
cific exposition doses from low dose CT scans only and 
from low dose CT scans plus PET CT scans are provided 
in appendix 2 (web tables S1 and S2).
Overall, 15 805 examinations were performed with 
eight detector row CT scans, 22 132 with 16 detector row 
CT scans, and 4291 with 64 detector row CT scans. 
Average effective doses for one low dose CT examina-
tion for the three CT scanners were 1.07 mSv (standard 
deviation 0.29), 1.05 mSv (0.27), and 0.64 mSv (0.15), 
respectively.
estimated risk of cancer from Ct screening
Table 3  shows lung cancers detected after 10 years of CT 
screening and lifetime attributable risk of lung cancer 
and major cancers by sex and age of COSMOS trial par-
ticipants. The lifetime attributable risk of cancer 
 incidence was extrapolated from the BEIR VII report to 
estimate lifetime attributable risks of lung cancer after 
10 years of CT screening. This lifetime attributable risk 
of lung cancer after 10 years of CT screening ranged 
between 5.5 per 10  000 participants (1 in 1811) for 
women starting screening at age 50-54, and 1.4 per 
10  000 participants (1 in 6908) for a man starting 
screening aged 65 and older. In the same two groups of 
women and men, lifetime attributable risks of major 
cancers ranged between 8.1 per 10 000 participants (1 in 
1229) and 2.6 per 10 000 participants (1 in 3898), respec-
tively (table 3).
Based on our exposure data applied to tables in the 
BEIR VII report, we estimated the number of lung can-
cers and major cancers induced by 10 years of low dose 
CT screening to be 1.5 and 2.4, respectively, correspond-
ing to a theoretical risk of induced major cancer of 
0.05% (2.4/5203). Compared with the number of lung 
cancers detected over 10 years, one radiation induced 
lung cancer would be expected for every 173 (259/1.5) 
lung cancers diagnosed, and one radiation induced 
major cancer would be expected for every 108 (259/2.4) 
lung cancers detected through screening.
The lifetime attributable risk of lung cancer was esti-
mated to be about four times greater for women aged 
50-54 years than for older men aged 65 and older (5.5 v 
1.4 per 10 000 participants). However, the lifetime 
attributable risk of major cancers was three times 
higher in the corresponding groups (8.1 v 2.6 per 10 000 
participants), reflecting differences in age and sex risk 
reported in the BEIR VII tables.
Figure 1 shows the estimated number of lung and 
major cancers induced by radiation for men and 
women, for 10 000 people screened. As expected, the 
risk of developing radiation induced cancer was higher 
for women at all ages, and the risk decreased in both 
sexes while the age of exposure increased. There were 
always fewer than five radiation induced cancers per 
10 000 people screened in men, and fewer than 10 per 
10 000 people screened in women.
table 1 | lung cancer screening rounds, annual and recall scans of low dose Ct, and Pet 
Ct scans administered to COsMOs trial participants
screening 
round
no of annual 
Ct scans
no (%) of first 
recall Ct 
scans per year
no (%) of second 
recall Ct scans 
per year
no (%) of Pet 
Ct scans per 
year
Baseline 5203 482 (9.3) 75 (1.4) 160 (3.1)
2nd year 4822 142 (2.9) 23 (0.5) 68 (1.4)
3rd year 4583 198 (4.3) 32 (0.7) 74 (1.6)
4th year 4380 251 (5.7) 47 (1.1) 62 (1.4)
5th year 4120 213 (5.2) 35 (0.8) 66 (1.6)
6th year 3856 197 (5.1) 24 (0.6) 62 (1.6)
7th year 3654 170 (4.7) 16 (0.4) 41 (1.1)
8th year 3449 118 (3.4) 14 (0.4) 35 (1.0)
9th year 3182 103 (3.2) 10 (0.3) 41 (1.3)
10th year 2732 91 (3.3) 6 (0.2) 26 (1.0)
Total No of scans 39 981 1965 282 635
CT=computed tomography; PET=positron emission tomography.
table 2 | Median cumulative organ dose and effective doses for screening and recall low dose Ct scans and Pet Ct scans at baseline, 3rd, 5th, and 10th 
screening round
Men Women
baseline 3rd year 5th year 10th year baseline 3rd year 5th year 10th year
No of participants 3439 3056 2768 1850 1764 1527 1352 884
Effective dose (mSv) 1.0 3.0 5.2 9.3 1.4 4.2 7.2 13.0
Organ dose (mGy):
 Breast — — — — 2.5 7.6 13.0 23.3
 Bladder 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.2
 Colon 0.2 0.7 1.2 2.2 0.2 0.6 1.1 2.0
 Oesophagus 1.4 4.5 7.7 13.6 1.8 5.6 9.5 16.9
 Gallbladder 1.5 4.6 7.9 14.0 1.3 4.2 7.2 12.9
 Heart 2.1 6.8 11.5 20.5 2.5 7.6 13.0 23.2
 Kidney 1.9 5.9 10.1 18.0 1.8 5.6 9.7 17.4
 Liver 1.9 6.1 10.4 18.4 2.1 6.6 11.2 20.0
 Lung 2.3 7.1 12.2 21.7 2.7 8.3 14.2 25.3
 Ovaries — — — — 0.1 0.2 0.3 0.6
 Marrow 0.8 2.5 4.3 7.6 0.9 2.8 4.7 8.4
 Skeleton 1.4 4.3 7.4 13.3 1.7 5.3 9.1 16.5
 Spleen 2.0 6.1 10.5 18.6 2.2 6.8 11.7 20.9
 Stomach 1.9 5.9 10.0 17.9 2.0 6.1 10.4 18.7
 Thyroid 0.2 0.6 1.1 1.9 0.5 1.6 2.8 5.2
 Uterus — — — — 0.1 0.2 0.3 0.5
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discussion
Principal findings
In this study, we showed that the median cumulative 
effective dose after 10 years of CT screening is roughly 9 
mSv for men and 13 mSv for women. By comparison 
with other diagnostic CT examinations, this means that 
an individual participating in a 10 year screening pro-
gramme of low dose CT would receive a dose similar to 
that delivered to another undergoing one standard CT 
scan to the chest (7-8 mSv) or abdomen-pelvis (13-14 
mSv).16 17  Furthermore, if we consider that the 10 year 
average dose from background sources in the USA is 
about 30 mSv, we can assume that 10 years of screening 
delivers only a third of the exposure to natural back-
ground radiation in the same period.18 19
Our study estimates that, after 10 years of low dose 
CT screening in 5203 asymptomatic high risk patients 
(age >50 and smoking history ≥20 pack years) with no 
history of cancer in the past five years, 1.5 lung cancers 
and 2.4 major cancers were theoretically induced by 
radiation. This corresponds to an additional overall risk 
of major cancer of 0.05% (2.4 in 5203 screened people). 
When compared with the number of cancers detected 
by CT screening in the same period, one major cancer is 
theoretically induced by radiation for roughly every 100 
detected.
As expected, the lifetime attributable risk for women 
was greater than for men at all ages, with a relative risk 
up to four times greater for lung cancer and up to three 
times greater for major cancers. This difference is 
related to the increased radiosensitivity of women 
 compared with men and to the risk of breast cancer 
associated with chest CT scans.4
strengths and weaknesses of the study
In this study, we analysed radiation exposure data 
assembled from a cohort of patients who were enrolled 
in a 10 year CT screening programme. To our knowl-
edge, this is the first analysis in a lung cancer screening 
population where a specific dose has been calculated 
for each of the 42 228 low dose CT scans—overcoming 
the limitation of using a fixed radiation exposure for all 
participants, as seen in previous studies.
One strength of this study was the dosimetry calcula-
tion, which was provided by an advanced software pro-
gram (Radimetrics) for each low dose CT scan. Although 
not a patient specific dosimetry, this software can calcu-
late organ doses and hence effective doses for six groups 
of women and five groups of men, according to their 
dimensions. Therefore, this size specific calculation of 
organ doses provides greater accuracy than software 
that uses only the standard reference patient for its cal-
culations. In this case, with a fixed acquisition protocol, 
we could observe no difference in organ and effective 
dose calculations. Variations in organ doses among par-
ticipants were also related to the number of low dose CT 
scans and PET CT scans received during the study and to 
the different doses delivered by the three CT scanners.
The assessment of cancer risk according to the BEIR 
committee is based on the linear no-threshold model 
and on data collected from environmental, occupa-
tional, and medical studies, and from atomic bomb sur-
vivors. The risk estimates of the BEIR VII report are thus 
based on risk models generated from studies on people 
exposed to high levels of radiation, and they are extrap-
olated to low doses using the linear no-threshold model 
for radiation risk. Various authors have discussed the 
weaknesses of the BEIR VII report, focusing on the lin-
ear no-threshold model7 20 21 and on uncertainties in the 
translation of risk from high doses and dose rates in the 
Japanese population to lower doses and dose rates in 
the US population.
A segment of the scientific community claims that 
there is a threshold for low dose radiation  carcinogenesis, 
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Fig 1 | lung cancers and major cancers theoretically 
induced per 10 000 people screened, according to sex and 
age at start of Ct screening for lung cancer
table 3 | number of lung cancers detected after 10 years of Ct screening and number of 
estimated lung and major cancers associated with radiation exposure, according to age 
and sex of COsMOs trial participants
Participant age 
and sex at start of 
screening
no of 
participants
no of lung 
cancers 
detected
no of estimated 
radiation induced lung 
cancers (lar/10 000)
no of estimated 
radiation induced major 
cancers* (lar/10 000)
50-54
 Male 1153 35 (1 in 33) 0.24 (2.1) 0.43 (3.7)
 Female 606 19 (1 in 32) 0.33 (5.5) 0.49 (8.1)
55-59
 Male 1114 56 (1 in 20) 0.21 (1.9) 0.38 (3.4)
 Female 611 31 (1 in 20) 0.31 (5.1) 0.44 (7.2)
60-64
 Male 716 54 (1 in 13) 0.12 (1.7) 0.22 (3.0)
 Female 345 13 (1 in 27) 0.16 (4.5) 0.21 (6.2)
≥65
 Male 456 41 (1 in 11) 0.07 (1.4) 0.12 (2.6)
 Female 202 10 (1 in 20) 0.08 (3.8) 0.10 (5.1)
All ages, both sexes 5203 259 detected 1.5 induced 2.4 induced
LAR=lifetime attributable risk.
*Cumulative LAR for cancers of the stomach, colon, liver, lung, bladder, thyroid, breast, ovaries, uterus, or leukaemia.
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and warns against quantitative estimation of health 
risks that might be too small to be observed or are 
non-existent below 50 mSv.22-24  However, so far there is 
not sufficient evidence to suggest that the risk from 
radiation exposure is non-existent below a certain 
dose. Therefore, the linear no-threshold model stands 
as a precautionary recommendation that follows a con-
servative approach. Furthermore, all the risk estimates 
in the tables of the BEIR VII report have been obtained 
as a consensus opinion of a committee, and the inferred 
risk at lower doses probably overestimates the risk of 
cancer induction.25
To estimate the risk of cancer in individuals, the opti-
mum approach would be to use specific organ doses 
and hence age and sex adjusted coefficients.26  The 
effective dose has been implemented mainly for protec-
tion purposes, and its use in medical practice as a 
 measure of individual risk goes beyond its intended 
purpose.14 27 Another factor to consider is that our 
results are related to the specific COSMOS study design, 
and different patient selection (eg, by age or smoking 
status) might lead to dissimilar results in terms of can-
cer risk.
As well as study population, screening nodule man-
agement has substantial implications for the overall 
radiation exposure and cancer risk. In fact, different 
thresholds of nodule size, interval follow-up, and the 
use of PET CT scans are determinant sources of varia-
tions. More conservative guidelines, as suggested by the 
American College of Radiology (Lung-RADS version 
1.0),28 could lead to lower population doses.
Comparison with other studies
In the National Lung Screening Trial, the effective dose 
estimates were 1.6 mSv and 2.4 mSv for one low dose CT 
scan for men and women, respectively.29 Our results 
show an effective dose at a baseline of 1.0 mSv for men 
and 1.4 mSv for women. These doses are 40% lower 
than in the National Lung Screening Trial, also consid-
ering the additional dose delivered by PET CT scans 
performed in our study. Study design, scanning param-
eters, and calculation methods might account for these 
differences. The scanning parameters at a typical study 
site in the National Lung Screening Trial are similar to 
those of our baseline data. However, the calculation 
method of organ dose and effective dose of the National 
Lung Screening Trial is based on software that does not 
take into account the patient’s body size. The estimated 
organ dose in the trial was 4.9 mGy to the breast, and 
nearly 5 mGy to the lungs for both men and women. By 
comparison, taking into account the patient’s body 
size, we found a dose of 2.5 mGy to the breast, and doses 
of 2.3 mGy and 2.7 mGy to the lungs for men and women, 
respectively. This difference between these results high-
lights how the estimates of organ and effective doses 
with software that takes into account the patient’s body 
size is an important source of variability.
The cumulative effective dose for the National Lung 
Screening Trial over three years was 4.8 mSv for men 
and 7.2 mSv for women. In the same period, we found a 
cumulative effective dose of 3.0 mSv for men and 4.2 
mSv for women (table 2 ). In our study, the cumulative 
effective dose, and the consequent risk of cancer, was 
the sum of radiation exposure both from low dose CT 
scans and PET CT scans. The contribution of one PET CT 
scan was 4.0 mSv, compared with the 10 year low dose 
CT cumulative exposure of 9.2 mSv and 12.9 mSv for 
men and women, respectively (table S2). Therefore, 
screening studies that do not include PET CT scans in 
their protocols could lead to a lower radiation exposure. 
The ITALUNG screening trial, after four rounds of 
screening, reported that 77.4% of the delivered dose was 
from annual low dose CT scans and 22.6% from further 
investigations (fluorodeoxyglucose-PET and CT guided 
biopsy).30 Further investigations assessing the role of 
study design in measuring radiation exposure are 
therefore needed.
Accurate risk prediction models can now quantify an 
individual’s risk of developing or dying from lung can-
cer, and help identify people at high enough risk to 
undergo screening.31 32  Little is known, however, about 
the additional risk of cancer caused by exposure to radi-
ation from screening itself. In a risk evaluation based 
on an assumed dose to the lung of 5.2 mGy, Brenner8 
estimated an additional lung cancer risk of 1.8% caused 
by annual lung CT screening. Our results, conversely, 
show a theoretical additional risk of 0.05% (2.4 cases of 
major cancers induced in 5203 people).
Further considerations and conclusions
Even if our results show that cumulative radiation expo-
sure after 10 years of low dose CT screening is substan-
tially limited, there are still possibilities for further 
reduction. An accurate patient selection can substan-
tially reduce the radiation exposure of low risk individ-
uals, and the definition of an accurate study design is 
essential for the improvement of the diagnostic flow-
chart, minimising unnecessary radiation exposure.
New CT scanners and optimised acquisitions proto-
cols can reduce the dose by up to 40%, as seen in the 
differences in effective doses among 8, 16, and 64 slice 
scanners reported in our results. In addition, according 
to our protocol, CT images were reconstructed by use of 
the standard filtered back projection. With the introduc-
tion of a new iterative reconstruction algorithm, it is 
now possible to achieve the same diagnostic image 
quality with a dose that is reduced by up to 80% com-
pared with standard filtered back projection.33-36
Another consideration is the detection of incidental 
findings on low dose CT scans.37 38 New findings could 
lead to additional radiation exposure through further 
testing. In the present study, we did not consider the 
additional exposure from examinations performed for 
collateral findings, resulting in a slight underestimation 
of overall cancer risk.
In conclusion, radiation exposure and cancer risk 
from CT screening, even if non-negligible, can be con-
sidered acceptable in light of the substantial mortality 
reduction associated with screening.
Contributors: CR and MB conceived and designed the study. PDM and 
DO acquired and analysed the data. PM carried out the statistical 
analysis. All authors drafted and revised the manuscript. All authors 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
have read and approved the final manuscript. CR and MB are the 
study guarantors and are responsible for the decision to submit for 
publication.
Funding: The COSMOS study was supported by the Italian Association 
for Cancer Research. The study sponsor was not involved in the study 
design, collection, analysis, and interpretation of data, or the writing of 
the article or the decision to submit it for publication. The authors 
were independent from study sponsor. The secondary analysis was 
not funded.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: 
support from the Italian Association for Cancer Research for the 
COSMOS study; no financial relationships with any organisations that 
might have an interest in the submitted work in the previous three 
years; no other relationships or activities that could appear to have 
influenced the submitted work.
Ethical approval: Not required.
Data sharing: No additional data available.
The lead author affirms that the manuscript is an honest, accurate, 
and transparent account of the study being reported; that no 
important aspects of the study have been omitted; and that any 
discrepancies from the study as planned have been explained.
This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different 
terms, provided the original work is properly cited and the use is 
non-commercial. See: http://creativecommons.org/licenses/
by-nc/4.0/.
1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J 
Clin 2015;65:5-29. doi:10.3322/caac.21254. 
2 Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial 
Research Team. Reduced lung-cancer mortality with low-dose 
computed tomographic screening. N Engl J Med 2011;365:395-409. 
doi:10.1056/NEJMoa1102873. 
3 Centers for Medicare & Medicaid Services. Decision memo for 
screening for lung cancer with low dose computed tomography 
(LDCT). (CAG-00439N). 2015. https://www.cms.gov/medicare-
coverage-database/details/nca-decision-memo.aspx?NCAId=274.
4  National Research Council. Health risks from exposure to low levels of 
ionizing radiation: BEIR VII—phase 2.National Academies Press, 2006.
5 Hendee WR, O’Connor MK. Radiation risks of medical imaging: 
separating fact from fantasy. Radiology 2012;264:312-21. 
doi:10.1148/radiol.12112678. 
6 Brenner DJ, Hall EJ. Cancer risks from CT scans: now we have data, 
what next?Radiology 2012;265:330-1. doi:10.1148/radiol.12121248. 
7 Calabrese EJ, O’Connor MK. Estimating risk of low radiation doses - a 
critical review of the BEIR VII report and its use of the linear 
no-threshold (LNT) hypothesis. Radiat Res 2014;182:463-74. 
doi:10.1667/RR13829.1. 
8 Brenner DJ. Radiation risks potentially associated with low-dose CT 
screening of adult smokers for lung cancer. Radiology 2004;231:440-
5. doi:10.1148/radiol.2312030880. 
9 McCunney RJ, Li J. Radiation risks in lung cancer screening programs: 
a comparison with nuclear industry workers and atomic bomb 
survivors. Chest 2014;145:618-24. doi:10.1378/chest.13-1420. 
10 Veronesi G, Bellomi M, Veronesi U, et al. Role of positron emission 
tomography scanning in the management of lung nodules detected at 
baseline computed tomography screening. Ann Thorac Surg 2007;84: 
959-65, discussion 965-6. doi:10.1016/j.athoracsur.2007.04.058. 
11 Veronesi G, Bellomi M, Mulshine JL, et al. Lung cancer screening with 
low-dose computed tomography: a non-invasive diagnostic protocol 
for baseline lung nodules. Lung Cancer 2008;61:340-9. doi:10.1016/j.
lungcan.2008.01.001. 
12 Radimetrics Enterprise Platform: dose management solution. Bayer 
HealthCare. 2014. https://www.radiologysolutions.bayer.com/
products/ct/dosemanagement/rep/.
13 Christy M, Eckerman KF. Specific absorbed fractions of energy at 
various ages from internal photon sources. 1987. http://citeseerx.ist.
psu.edu/viewdoc/download?doi=10.1.1.453.354&rep=rep1&type=pdf.
14  International Commission on Radiological Protection. The 2007 
Recommendations of the International Commission on Radiological 
Protection. ICRP publication 103. Ann ICRP 2007;37:1-332.
15 Icrp . Radiation dose to patients from radiopharmaceuticals. 
Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved 
by the Commission in October 2007. Ann ICRP 2008;38:1-197.
16 Mettler FA Jr, , Huda W, Yoshizumi TT, Mahesh M. Effective doses in 
radiology and diagnostic nuclear medicine: a catalog. Radiology 
2008;248:254-63. doi:10.1148/radiol.2481071451. 
17 Osei EK, Darko J. A survey of organ equivalent and effective doses from 
diagnostic radiology procedures. ISRN Radiol 2012;2013:204346.
18 United Nations Scientific Committee on the Effects of Atomic 
Radiation. UNSCEAR 2008 report to the General Assembly. Sources 
and effects of ionizing radiation. United Nations, 2010. 
19 National Council on Radiation Protection and Measurements. Ionizing 
radiation exposure of the population of the United States. 2009. NCRP 
report 160.
20 Tubiana M. Dose-effect relationship and estimation of the 
carcinogenic effects of low doses of ionizing radiation: the joint report 
of the Académie des Sciences (Paris) and of the Académie Nationale 
de Médecine. Int J Radiat Oncol Biol Phys 2005;63:317-9. 
doi:10.1016/j.ijrobp.2005.06.013. 
21 Brooks AL, Dauer LT. Advances in radiation biology: effect on nuclear 
medicine. Semin Nucl Med 2014;44:179-86.  doi:10.1053/j.
semnuclmed.2014.03.004. 
22 Hendee WR. International Organization for Medical Physics. 
International organization for medical physics. Policy statement of the 
international organization for medical physics. Radiology 
2013;267:326-7. doi:10.1148/radiol.13130567. 
23 Uncertainty in risk assessment: Position of the health physics society. 
Health physics society website. 2013. http://hps.org/documents/
riskassessment_ps008-2.pdf.
24 Radiation risk in perspective: Position of the health physics society. 
Health physics society website. 2010. https://hps.org/documents/
radiationrisk.pdf.
25 Scott BR. Low-dose radiation risk extrapolation fallacy associated with 
the linear-no-threshold model. Hum Exp Toxicol 2008;27:163-8. 
doi:10.1177/0960327107083410. 
26 McCollough CH, Christner JA, Kofler JM. How effective is effective dose 
as a predictor of radiation risk?AJR Am J Roentgenol 2010;194:890-6. 
doi:10.2214/AJR.09.4179. 
27 Harrison JD, Balonov M, Martin CJ, et al. Use of effective dose. Ann 
ICRP 2016;45(Suppl):215-24. doi:10.1177/0146645316634566. 
28 American College of Radiology. Lung CT Screening Reporting and Data 
System (Lung-RADS). https://www.acr.org/Quality-Safety/Resources/
LungRADS.
29 Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose 
associated with low-dose chest CT of average-size participants in the 
National Lung Screening Trial. AJR Am J Roentgenol 2011;197:1165-9. 
doi:10.2214/AJR.11.6533. 
30 Mascalchi M, Mazzoni LN, Falchini M, et al. Dose exposure in the 
ITALUNG trial of lung cancer screening with low-dose CT. Br J Radiol 
2012;85:1134-9. doi:10.1259/bjr/20711289. 
31 Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk 
prediction to select smokers for screening CT--a model based on the 
Italian COSMOS trial. Cancer Prev Res (Phila) 2011;4:1778-89. 
doi:10.1158/1940-6207.CAPR-11-0026. 
32 Tammemagi MC, Lam S. Screening for lung cancer using low dose 
computed tomography. BMJ 2014;348:g2253. doi:10.1136/bmj.g2253. 
33 Yamada Y, Jinzaki M, Tanami Y, et al. Model-based iterative 
reconstruction technique for ultralow-dose computed tomography of 
the lung: a pilot study. Invest Radiol 2012;47:482-9. doi:10.1097/
RLI.0b013e3182562a89. 
34 Mathieu KB, Ai H, Fox PS, et al. Radiation dose reduction for CT lung 
cancer screening using ASIR and MBIR: a phantom study. J Appl Clin 
Med Phys 2014;15:4515.
35 den Harder AM, Willemink MJ, de Ruiter QMB, et al. Achievable dose 
reduction using iterative reconstruction for chest computed 
tomography: A systematic review. Eur J Radiol 2015;84:2307-13. 
doi:10.1016/j.ejrad.2015.07.011. 
36 Rampinelli C, Origgi D, Vecchi V, et al. Ultra-low-dose CT with 
model-based iterative reconstruction (MBIR): detection of 
ground-glass nodules in an anthropomorphic phantom study. Radiol 
Med 2015;120:611-7. doi:10.1007/s11547-015-0505-5. 
37 Rampinelli C, Preda L, Maniglio M, et al. Extrapulmonary malignancies 
detected at lung cancer screening. Radiology 2011;261:293-9. 
doi:10.1148/radiol.11102231. 
38 van de Wiel JC, Wang Y, Xu DM, et al. NELSON study group. 
Neglectable benefit of searching for incidental findings in the 
Dutch-Belgian lung cancer screening trial (NELSON) using low-dose 
multidetector CT. Eur Radiol 2007;17:1474-82. doi:10.1007/
s00330-006-0532-7. 
Appendix 1: Supplementary material
Appendix 2: Web tables
